Probiotics are defined as "live microorganisms that, when administered in adequate amounts, confer a health benefit on the host." However, probiotic efficacy is highly strain-specific; different strains of the same species may offer entirely distinct health benefits.
Taking Lactobacillus rhamnosus GG (LGG) as an example: this specific strain has been shown to prevent antibiotic-associated diarrhea and acute diarrhea in children, but other strains of the same species may not offer this benefit. Bifidobacterium longum 1714 has been found to improve stress perception and cortisol response, yet other strains of B. longum may not provide the same effect.
Strain-specific mechanisms operate at multiple levels: genomic differences lead to distinct metabolite profiles (e.g., some strains produce GABA, others butyrate); variations in surface proteins affect interactions with intestinal epithelial cells; and differences in colonization capacity determine how long the strain persists in the gut.
In functional medicine product development, probiotic formulations must be designed at the strain level, selecting only specific strains validated by randomized controlled trials (RCTs). Common clinically validated strains include: LGG (for diarrhea prevention), B. lactis HN019 (for immune modulation), S. boulardii CNCM I-745 (for antibiotic-associated diarrhea), and B. longum 1714 (for stress management).
Dynas Group (HK) offers multi-strain probiotic blends in the GI Support Series (12 + clinically validated strains, including Lactobacillus, Bifidobacterium, and Akkermansia postbiotics), available as capsules or powders. Formulations are designed around a gut microbiome support logic: strain specificity, multi-target synergy, and live-cell stability.
